Clinical Trials
3 trialsNCT00813956 2016-03-17
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT01173497 2016-03-17
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Sanofi
Phase 2 Completed
NCT00540358 2012-12-28
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
Sanofi
Phase 2 Completed